Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 11, 2013

USP Forms Elemental Impurities Advisory Group

USP appoints regulatory experts to elemental impurities implementation advisory group.

The US Pharmacopeial Convention (USP) has formed the Elemental Impurities Implementation Advisory Group and appointed members to the group from various regulatory agencies. The group will recommend implementations and general chapter adjustments to USP and will report to the Chemical Analysis Expert Committee.

According to USP, the Advisory Group was formed in accordance with the Bylaws of the USP Convention, which state, “The EVP–CEO may appoint advisory bodies to advance the work of the Council of Experts and the Convention and provide advice to staff on policy matters.” 

Dr. Roger Williams, EVP–CEO and Chair, Council of Experts, appointed the following members to the group:

  • Jon Clark, FDA

  • David Gaugh, GPhA

  • John Kauffman, FDA and ICH Q3D Rapporteur (current)

  • David Klug, IPEC–Americas

  • John Leighton, FDA

  • Robert Osterberg, USP Toxicology Expert Committee

  • John Punzi, CHPA

  • Mark Schweitzer, ICH Q3D Rapporteur (through Step 2)

  • Phyllis Walsh, NJPQCA 

USP will keep stakeholders informed through web postings on the Elemental Impurities Key Issues page, including summaries of the Advisory Group’s deliberations.


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.